Clinical Trial Update: Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) [Phase 1, Phase 2]

View source ↗

Summary

This document describes a Phase 1/2 trial evaluating the combination of bortezomib and bevacizumab in advanced or recurrent renal cell carcinoma. The current st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Velcade (bortezomib)

Snippet

Sponsor: University of Southern California | Conditions: Renal Cell Cancer | Phase 1, Phase 2 | Status: UNKNOWN